Myocardial Perfusion Echocardiography to Detect Human Heart Transplant

Brigham and Women's Hospital1 site in 1 country10 target enrollmentJanuary 2015

ConditionsHeart Transplantation

InterventionsOptison

DrugsOptison

Overview

Phase: N/A
Intervention: Optison
Conditions: Heart Transplantation
Sponsor: Brigham and Women's Hospital
Enrollment: 10
Locations: 1
Primary Endpoint: Global and regional microvascular myocardial perfusion
Status: Terminated
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

The primary objective of this proposal is to show the efficacy of contrast enhanced ultrasonography in detecting heart transplant rejection in humans. The secondary objective is to demonstrate the efficacy of this technique in generating data which allow for the assessment of short and long term outcomes.

Registry

clinicaltrials.gov

Start Date

January 2015

End Date

December 2019

Last Updated

2 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Brigham and Women's Hospital

Responsible Party

Principal Investigator

Michael Givertz, MD

Medical Director, Heart Transplant and Mechanical Circulatory Support

Brigham and Women's Hospital

Eligibility Criteria

Inclusion Criteria

•All adult subjects (ages 18 to 75) who have undergone heart transplant at Brigham and Women's Hospital

Exclusion Criteria

•hemodynamic instability (e.g., systolic blood pressure \< 90 mmHg)
•atrial fibrillation with rapid ventricular response (e.g., heart rate \> 120 bpm)
•premature atrial or ventricular complexes of a frequency that will not allow adequate echocardiographic assessment
•poor acoustic windows
•inability to provide informed consent
•any contraindication listed in the Optison package insert (i.e., history of an allergic reaction)